Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth report from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with Covid 19.
This report describes and evaluates the global anti-asthmatics and COPD drugs market. It covers two five-year periods, one three-year period, and one six-year period including, 2015 to 2019, termed the historic period, and 2019 to 2023 forecast period, 2023-2025 forecast period and 2025 -2030 the forecast period.
The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015. The global anti-asthmatics and COPD drugs market is expected to grow from $40,162.1 million in 2019 to about $49,384.3 million in 2020 due to an increase in demand for the use of anti-asthmatics and COPD drugs in the treatment of Covid-19 patients. The global anti-asthmatics and COPD drugs market is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023. Also the market is expected to growth to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%.
Growth in the historic period resulted from increased prevalence of respiratory diseases, increasing incidence of tobacco smoking, global warming, geriatric population, new methods for drug discovery, and rise in healthcare expenditure. Factors that negatively affected growth in the historic period were expiration of patents, and political uncertainties.
Going forward, increased popularity of e-cigarettes/vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat covid-19 patients, and increasing consumption of fats are expected to drive the market. Factors that could hinder the growth of the anti-asthmatics and COPD drugs market in the future include side effects associated with respiratory drugs, reduction in free trade, and stringent regulations.
The anti-asthmatics and COPD drugs market is segmented by type of drug class into combination drugs, bronchodilators, monoclonal antibodies, and anti-inflammatory drugs. The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market by drug class, accounting for $14,964.9 million or 37.3% of the total market in 2019. The monoclonal antibodies market is expected to be the fastest-growing segment going forward at a CAGR of 7.4%.
The anti-asthmatics and COPD drugs market is segmented by type of end user into asthma patients, and COPD patients. The asthma patients was the largest segment of the anti-asthmatics and COPD drugs market by end user, accounting for $ 24,791.3 million or 61.7% of the total market in 2019. The COPD patients market is expected to be the fastest-growing segment going forward at a CAGR of 4.5%.
The anti-asthmatics and COPD drugs market is segmented by distribution channel into general pharmacies, hospital pharmacies, and online retailers. The general pharmacies was the largest segment of the anti-asthmatics and COPD drugs market by distribution channel, accounting for $ 26,424.3 million or 65.8% of the total market in 2019. The online retailers market is expected to be the fastest-growing segment going forward at a CAGR of 9.6%.
The anti-asthmatics and COPD drugs market is segmented by age group into below 5 years, 5 to 14 years, 15-69 years, and 70+ years. The 15-69 years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $20,220.7 million or 50.3% of the total market in 2019.
The anti-asthmatics and COPD drugs market is segmented by therapy into preventive, and curative. The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $21,791.0 million or 54.3% of the total market in 2019.
The anti-asthmatics and COPD drugs market is segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $29,360.8 million or 73.1% of the total market in 2019.
The anti-asthmatics and COPD drugs market is segmented by prescription into prescription, and OTC. The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $37,521.9 million or 93.4% of the total market in 2019.
The anti-asthmatics and COPD drugs market is segmented by drug type into branded, and generics. The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $38,378.9 million or 95.6% of the total market in 2019.
North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.7% of the global market in 2019. It was followed by Asia Pacific, Western Europe and the other regions. Going forward, the fastest growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and the Middle East, where growth will be at CAGRs of 8.1% and 5.7% respectively from 2019-2023.
The global anti-asthmatics and COPD drugs market is consolidated, with a small number of large players. The top ten competitors in the market made up to 64.6% of the total market in 2019. Major players in the market include GlaxoSmithKline plc., AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis and others.
COVID-19 is an infectious disease caused by a newly discovered corona virus. COVID-19 which originated in the Wuhan Province of China, in December 2019 has now spread across the world. The unprecedented outbreak of corona virus has caused a surge in demand for anti-asthmatics and COPD drugs as some anti-asthmatics and COPD drugs such as albuterol are being used in the treatment of COVID. With governments across the world advising people to practice social distancing, individuals are stocking up anti-asthmatics and COPD medications, increasing the demand for these drugs.
The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in combination drugs market, which will gain $2,789.8 million of global annual sales by 2023. The top growth potential in the anti-asthmatics and COPD drugs market by end user will arise in the asthma patients market, which will gain $4,060.0 million of global annual sales by 2023. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $3,593.2 million of global annual sales by 2023. The anti-asthmatics and COPD drugs market size will gain the most in the USA at $2,283.6 million. Market-trend-based strategies for the anti-asthmatics and COPD drugs market include focusing on increasing the number of collaborations to expand business portfolios, investing in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, investing in generic drugs to counter the intense competition, developing combination drugs, and developing biologics. Player-adopted strategies in the anti-asthmatics and COPD drugs industry include investing in scientific and technical excellence to develop and launch a pipeline of new products, strengthening anti-asthmatics and COPD drugs business through the expansion of product portfolio, and expanding business through strategic investments focusing on expansion of manufacturing operations.
To take advantage of the opportunities, The Business Research Company recommends the anti-asthmatics and COPD drugs companies to focus on personalized medicines, focus on increasing the production temporarily during the COVID-19 pandemic, leverage e-commerce to maximize reach and revenues, provide competitively priced offerings in low-income countries to reach new users, and focus on increasing awareness on asthma and COPD.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
Description:
Where is the largest and fastest growing market for the anti-asthmatics and COPD drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global anti-asthmatics and COPD drugs market opportunities and strategies to 2030: COVID 19 Implications and Growth report from the Business Research Company answers all these questions and many more.
The report covers the following chapters
- Executive Summary –The executive summary section of the report gives a brief overview and summary of the report.
- Report Structure – This section gives the structure of the report and the information covered in the various sections.
- Introduction -The introduction section of the report gives brief introduction about segmentation by geography and segmentation by type.
- Market Characteristics –The market characteristics section of the report defines and explains the anti-asthmatics and COPD drugs market. This chapter includes different goods covered in the report and basic definitions.
- Supply Chain –The supply chain section of the report defines and explains the key players in the anti-asthmatics and COPD drugs industry supply chain.
- Product Analysis –The product analysis section of the report describes the leading products in the market along with key features and differentiators for those products.
- Top 10 Leading Drugs Sales–The section describes list of top 10 drugs and their sales in the anti-asthmatics and COPD drug market in 2019. It briefs on the drug chemical composition, drug class and the manufacturers involved in manufacturing and selling of these leading drugs in the anti-asthmatics and COPD drugs market.
- Patent Analysis Of Leading Drugs–The section briefs on the patent analysis of the leading drugs in the anti-asthmatics and COPD drugs market, by focusing on the leading drugs’ patent expiry and emergence of the generic drugs in the market.
- Customer Information– This chapter covers recent customers’ trends/preferences in the global anti-asthmatics and COPD drugs market.
- Impact Of COVID-19- This section describes the impact of COVID-19 on the anti-asthmatics and COPD drugs market.
- Trends And Strategies – This chapter describes the major trends shaping the global anti-asthmatics and COPD drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Asthma And COPD Prevalence Overview–This section describes about asthma and COPD and their prevalence in the major countries.
- Global Market Size And Growth – This section contains the global historic (2015-2019) and forecast (2019 - 2023, 2025 and 2030) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
- Regional And Country Analysis – This section contains the historic (2015-2019), forecast (2023, 2025 and 2030) market value and growth and market share comparison by region and countries.
- Market Segmentation –This section contains the market values (2015-2029, 2023, 2025 and 2030) and analysis for different segments in the market.
- Regional Market Size And Growth–This section contains the region’s market size (2019), historic and forecast (2015-2019, 2023, 2025 and 2030) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
- Competitive Landscape – This section covers details on the competitive landscape of the global anti-asthmatics and COPD drugs market, estimated market shares and company profiles of the leading players.
- Key Mergers And Acquisitions – This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Background – This section describes the respiratory diseases drugs market of which the anti-asthmatics and COPD drugs market is a segment. This chapter includes the respiratory diseases drugs market 2015-23 values, and regional analyses for the respiratory diseases drugs market.
- Market Opportunities And Strategies– This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations – This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-asthmatics and COPD drugs providers in terms of product offerings, geographic expansion, price offerings, marketing strategies and target groups.
- Appendix – This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- By Type Of Drug Class: Combination Drugs; Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs
- By Type Of End-User: Asthma Patients; COPD Patients
- By Distribution Channel: General Pharmacies; Hospital Pharmacies; Online Retailers
- By Age Group: Below 5 Years; 5 to 14 Years; 15-69 Years; 70+ Years
- By Type Of Therapy: Preventive; Curative
- By Route Of Administration: Inhaled; Intravenous and Subcutaneous; Oral
- By Type Of Prescription: Prescription; OTC
- By Type Of Drug: Branded; Generics
Companies Mentioned: GlaxoSmithKline plc.; AstraZeneca plc.; Boehringer Ingelheim; F. Hoffmann-La Roche Ltd; Novartis
Countries: China, India, Japan, Australia, Indonesia, South Korea, USA, Russia, UK, Germany, France, Brazil.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Time series: Two five-year periods, one three-year period and one six-year period.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
US $
Euro €
GBP £